Andrew Holtz updates us on what he calls Pfizer’s “attempts to co-opt journalists” by sponsoring various journalism “events.”
As Holtz notes, it’s an old and sore subject with me. Several concerned journalists within the past two years have criticized the National Press Foundation (NPF) for accepting Pfizer money for all-expenses-paid trips for journalists to come to Washington to learn about cancer and Alzheimer’s disease issues – both of which topics are in Pfizer’s product line. NPF has now started accepting Novo Nordisk money for a journalism event on diabetes issues as well.
I was scheduled to meet with NPF staff to discuss my concerns last January but the meeting was cancelled because of a DC snowfall. I have simply been too busy to continue to pursue this issue and have let it gather dust, so I am pleased to see that others will not let it die.
Indeed, we should be having an international dialogue on pharma’s influence – something I wrote about last year after an international “Selling Sickness” conference in Amsterdam.
One international voice has weighed in – Italian journalist Maria Amelia Beltramini Boveri – whom I met at a European health journalism event in the UK, argues against pharma-sponsored press events. She encourages a discussion on a listserv of European journalists.
Nice work.
Opinions on other issues in news, journals, PR, advertising, marketing
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like